Does Ezetimibe Lower Cardiovascular Risk Through Lipid Changes?
Yes, ezetimibe reduces cardiovascular risk primarily by lowering low-density lipoprotein cholesterol (LDL-C). It inhibits cholesterol absorption in the small intestine via the NPC1L1 protein, decreasing intestinal cholesterol uptake by 50-60% and reducing LDL-C by 15-25% when used alone.[1][2]
Key Evidence from IMPROVE-IT Trial
The IMPROVE-IT trial (2014) tested ezetimibe/simvastatin versus simvastatin alone in 18,144 post-acute coronary syndrome patients. The ezetimibe arm achieved lower LDL-C (53.7 mg/dL vs. 69.5 mg/dL at one year) and reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, unstable angina, stroke, or revascularization by 6.4% (HR 0.936, 95% CI 0.89-0.99; p=0.016).[3] Benefits emerged after two years, with LDL-C below 70 mg/dL linked to fewer events, supporting lipid-lowering as the mechanism.
How It Compares to Statins Alone
Ezetimibe adds to statin therapy when LDL-C targets aren't met. In IMPROVE-IT, it intensified lipid reduction without increasing muscle or liver risks beyond statins. Meta-analyses confirm 10% LDL-C drop correlates with 20-25% relative risk reduction in major vascular events, similar to statin effects per milligram reduction.[4]
What About Non-Lipid Effects?
No strong evidence supports cardiovascular benefits independent of LDL-C lowering. Trials like SEAS and SHARP showed risk reduction proportional to LDL-C changes, with no pleiotropic effects (e.g., on inflammation or plaque stability) beyond lipids.[2][5] Ongoing studies like EWTOPIA 75 explore it in statin-intolerant patients.
Who Benefits Most and Current Guidelines?
Patients with atherosclerotic cardiovascular disease (ASCVD) or high risk benefit when LDL-C remains above 70 mg/dL on maximal statin. ACC/AHA guidelines recommend adding ezetimibe (10 mg daily) as non-statin therapy, ahead of PCSK9 inhibitors for cost and tolerability.[6] It's generic, priced under $10/month.
[1] Ezetimibe mechanism - NEJM
[2] Ezetimibe review - Circulation
[3] IMPROVE-IT results - NEJM
[4] LDL-C meta-analysis - Lancet
[5] SHARP trial - NEJM
[6] ACC/AHA lipid guidelines